Alcidion (ASX:ALC) Wins Dual AI Healthcare Approval After Swinging to Profit- Time to Buy or Wait?

Alcidion Clears a Key AI Approval Hurdle Alcidion Group (ASX: ALC) hit a regulatory milestone that could open up its next phase of growth. The company has secured Class I…

ByUjjwal Maheshwari

17

Feb 2026

Healthcare Stocks

Ansell (ASX:ANN) Proves It Can Pass On Trump’s Tariffs – But With Shares Down 13%, Is It a Buy?

Ansell Shrugs Off Tariffs with Strong Pricing Power Ansell (ASX: ANN) reported half-year results on Monday that told a story most ASX investors weren't expecting. Revenue barely moved, up just…

ByUjjwal Maheshwari

14

Feb 2026

Healthcare Stocks

Why ASX Healthcare Stocks Are Crashing- and Which One Looks Like a Buy

ASX healthcare stocks are crashing- which one is worth buying now? Three of Australia's most premium ASX healthcare stocks have been crushed in the same week. CSL (ASX: CSL) has…

ByUjjwal Maheshwari

12

Feb 2026

Healthcare Stocks

A Blood Test Instead of a Colonoscopy? Rhythm Biosciences (ASX:RHY) Takes Its First Commercial Step

Rhythm Biosciences Starts ColoSTAT Pilot, Revenue Still Unclear Rhythm Biosciences (ASX: RHY) just hit a milestone the market has been waiting for, enrolling its first doctor in the ColoSTAT Access…

ByUjjwal Maheshwari

07

Feb 2026

Healthcare Stocks

Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the…

ByUjjwal Maheshwari

05

Feb 2026

Healthcare Stocks

Island Pharmaceuticals (ASX:ILA) Raises A$9M as FDA Confirms Galidesivir Pathway: Is This Small-Cap Biotech a Buy?

Island Pharmaceuticals jumps after FDA backs galidesivir pathway Island Pharmaceuticals (ASX: ILA) surged as much as 23% to an intraday high of A$0.48 on Wednesday before settling at A$0.42, after…

ByUjjwal Maheshwari

04

Feb 2026

Healthcare Stocks

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Neuren Pharmaceuticals: Is the 10% drop a buy signal? Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to A$14.63 from a previous close of A$16.25. The sell-off came…

ByUjjwal Maheshwari

02

Feb 2026

Healthcare Stocks

Is it Time to Buy ResMed (ASX:RMD)? It is Crushing the Ozempic Fear Narrative with New Data!

ResMed data shows GLP-1 users use CPAP more Is it time to buy ResMed (ASX: RMD)? Well, the company is having good momentum right now - it delivered another strong…

ByUjjwal Maheshwari

29

Jan 2026

Healthcare Stocks

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

Telix Pharmaceuticals Shares Slide After Regulatory Setbacks Telix Pharmaceuticals (ASX: TLX) has had a brutal twelve months. Shares have fallen around 63% from their February 2025 all-time high of A$31.97…

ByUjjwal Maheshwari

24

Jan 2026

Healthcare Stocks

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Aroa Biosurgery adds new trauma study as profits turn positive Aroa Biosurgery (ASX: ARX) shares have seen increased activity this week, hovering around the A$0.70 level following news that…

ByUjjwal Maheshwari

Alcidion (ASX:ALC) Wins Dual AI Healthcare Approval After Swinging to Profit- Time to Buy or Wait?

Ansell (ASX:ANN) Proves It Can Pass On Trump’s Tariffs – But With Shares Down 13%, Is It a Buy?

Why ASX Healthcare Stocks Are Crashing- and Which One Looks Like a Buy

A Blood Test Instead of a Colonoscopy? Rhythm Biosciences (ASX:RHY) Takes Its First Commercial Step

Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Island Pharmaceuticals (ASX:ILA) Raises A$9M as FDA Confirms Galidesivir Pathway: Is This Small-Cap Biotech a Buy?

Neuren (ASX:NEU) Crashes 10% on EU Setback: Is This a Buying Opportunity?

Is it Time to Buy ResMed (ASX:RMD)? It is Crushing the Ozempic Fear Narrative with New Data!

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

PLS Group (ASX:PLS) Hits Record High on...

Narryer Metals (ASX:NYM) Tim Goyder Back...

Sovereign Metals (ASX:SVM) DFS lands,$2....

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here